Eli Lilly (LLY) Operating Expenses (2009 - 2026)

Eli Lilly (LLY) has reported Operating Expenses for 18 consecutive years, with $6.7 billion the latest figure, recorded in Q1 2026.

• Operating Expenses for Q1 2026 came in at $6.7 billion, up 28.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.4 billion (up 24.48% YoY), and the FY2025 annual result was $24.9 billion, up 21.86% from the prior year.
• Operating Expenses was $6.7 billion for Q1 2026 at Eli Lilly, down from $7.0 billion in the prior quarter.
• Over five years, Operating Expenses peaked at $7.0 billion in Q4 2025 and troughed at $3.2 billion in Q1 2022.
• Average Operating Expenses over 5 years is $4.9 billion, with a median of $4.6 billion recorded in 2023.
• Year-over-year, Operating Expenses slipped 8.43% in 2022 and jumped 33.69% in 2025.
• Over 5 years, Operating Expenses stood at $3.7 billion in 2022, then climbed by 23.89% to $4.6 billion in 2023, then increased by 27.13% to $5.8 billion in 2024, then rose by 21.15% to $7.0 billion in 2025, then declined by 4.19% to $6.7 billion in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $6.7 billion in Q1 2026, $7.0 billion in Q4 2025, and $6.6 billion in Q3 2025.